News

Winter Clinical Miami 2026 speakers share buy-and-bill and real estate tactics for dermatologists to boost revenue and protect cash flow.

Gary Goldenberg, MD shares branding, pricing, and tech tips to grow a profitable aesthetic dermatology practice at Winter Clinical Miami 2026.

Over 70% of evaluable patients achieved near-clear or clear skin after nearly 3 years of treatment with nemolizumab.

At Winter Clinical Miami 2026, Mona Shahriari, MD, revealed a comprehensive roadmap to launch and scale dermatology clinical trials.

As Winter Clinical kicks off in Aventura, Florida, scroll through and find some faces familiar to Dermatology Times who are presenting at the meeting.

Winter Clinical Miami 2026 kicks off today with the latest dermatology updates—let us know if you're attending and stay tuned for live coverage, pearls, and interviews.

In a Derm Dispatch discussion, Renata Block, DMSc, MMS, PA-C, and Lauren Madigan, MD, review practical strategies for diagnosing and managing cutaneous mastocytosis across age groups.

Patricia M. Delgado, DNP, AGPCNP, DCNP, PMHNP, and Shanna Miranti, MPAS, PA-C, discuss how “taking off the clinician mask” can strengthen trust and improve shared decision-making in the exam room.

Review our content from the month of February that recognizes patients and clinicians with skin of color.

Dermatology Times is looking back on the top stories in dermatology from the month of February.

This case involved a young patient with mild to moderate hidradenitis suppurativa (HS) of the axillae, characterized by intermittent, limited lesions without tunneling or scarring. Although seemingly routine, it prompted deeper reflection.

Explore the top headlines of the month, including insights on regulatory updates, expert pearls, and more.

Dermatology Times is recapping our exclusive expert interviews from the month of February.

Dermatology Times recently concluded its second annual Horizons in Advanced Practice meeting in Tampa, Florida, featuring nurse practitioners and physician assistants from across the country.

Learn more about the in-depth topics covered in the February 2026 print issue of Dermatology Times.

The first case involved a middle-aged patient with severe, long-standing hidradenitis suppurativa (HS) marked by years of active disease with extensive sinus tracts, dense scarring, chronic drainage, frequent flares, constant pain, limited mobility, and a daily life centered around symptom management.

The FDA has assigned a Prescription Drug User Fee Act target action date of December 12, 2026.

Barzolvolimab is a humanized monoclonal antibody that inhibits the KIT receptor, aiming to reduce mast cell survival and activity in chronic spontaneous urticaria.

Revance and Teoxane’s RHA Dynamic Volume earns FDA approval for midface lift, delivering natural movement and lasting cheek contour in supporting clinical trials.

More than 57% of patients with ACD reported moderate to severe quality-of-life impairment, with symptoms and embarrassment among the most affected areas.

In a recent Expert Perspectives video series, Omar Noor, MD, discussed the complexity of chronic hand eczema and how a topical pan-JAK inhibitor can improve quality of life.

Joni Jefferson, DO, spotlights skin of color dermatology, safer lasers, mentorship, and the future of aesthetic medicine during Black History Month.

In an interview with Dermatology Times, Michael O’Donoghue, MD, describes how a standardized protocol supports efficient and consistent delivery of photodynamic therapy.

Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of February.

Transcriptomic analysis revealed that chronic hand eczema shares overlapping immune signatures with both atopic dermatitis and psoriasis.

BE HEARD long-term data show bimekizumab (Bimzelx) IL‑17A/F reduces hidradenitis suppurativa draining tunnels while boosting IHS4 and quality of life.

In a 52-week phase 3 study, CT-P43 demonstrated sustained efficacy comparable to reference ustekinumab in adults with moderate to severe plaque psoriasis.

A JAMA Dermatology study found that US veterans with documented Agent Orange exposure had approximately 30% higher odds of developing acral melanoma compared with unexposed veterans.

HS is frequently misdiagnosed for 7 to 10 years because its symptoms resemble conditions like inflamed epidermal cysts, nodulocystic acne, and furuncles.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!